147 related articles for article (PubMed ID: 22947101)
1. Acute inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alfa-2a in a patient with chronic hepatitis C virus infection: a case report.
Lahbabi M; Ghissassi M; Belahcen F; Ibrahimi SA; Aqodad N
J Med Case Rep; 2012 Sep; 6():278. PubMed ID: 22947101
[TBL] [Abstract][Full Text] [Related]
2. Acute inflammatory demyelinating polyneuropathy associated with pegylated interferon alpha 2a therapy for chronic hepatitis C virus infection.
Khiani V; Kelly T; Shibli A; Jensen D; Mohanty SR
World J Gastroenterol; 2008 Jan; 14(2):318-21. PubMed ID: 18186575
[TBL] [Abstract][Full Text] [Related]
3. Guillain-Barre syndrome associated with peginterferon alfa-2a for chronic hepatitis C: A case report.
Niazi MA; Azhar A; Tufail K; Feyssa EL; Penny SF; McGregory M; Araya V; Ortiz JA
World J Hepatol; 2010 Apr; 2(4):162-6. PubMed ID: 21160989
[TBL] [Abstract][Full Text] [Related]
4. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
5. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
[TBL] [Abstract][Full Text] [Related]
6. Pericarditis and chronic inflammatory demyelinating polyneuropathy during therapy with pegylated interferon alfa-2a for chronic hepatitis C.
Nishio K; Konndo T; Okada S; Enchi M
World J Hepatol; 2010 Sep; 2(9):358-61. PubMed ID: 21161021
[TBL] [Abstract][Full Text] [Related]
7. [Peripheral polyneuropathy and bilateral optic neuropathy during treatment of chronic hepatitis C].
Chrissafidou A; Musch E
Dtsch Med Wochenschr; 2009 Apr; 134(18):927-30. PubMed ID: 19384811
[TBL] [Abstract][Full Text] [Related]
8. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
[TBL] [Abstract][Full Text] [Related]
9. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Brodin H; Cave C; Waugh N; Price A; Gabbay J
Health Technol Assess; 2004 Oct; 8(39):iii-iv, 1-125. PubMed ID: 15461877
[TBL] [Abstract][Full Text] [Related]
10. [A case of chronic inflammatory demyelinating polyradiculoneuropathy after treatment with pegylated interferon α-2a in a patient with chronic hepatitis B virus infection].
Naito H; Takeda I; Segawa A; Tsuge M; Maruyama H; Matsumoto M
Rinsho Shinkeigaku; 2016 Oct; 56(10):672-677. PubMed ID: 27680223
[TBL] [Abstract][Full Text] [Related]
11. [Chronic inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alpha 2b in a patient with HIV/HCV coinfection: case report].
Bassetti BR; Trés ES; Ciríaco JG; Pinto Neto LF
Rev Soc Bras Med Trop; 2010; 43(1):89-91. PubMed ID: 20305976
[TBL] [Abstract][Full Text] [Related]
12. Merimepodib, pegylated interferon, and ribavirin in genotype 1 chronic hepatitis C pegylated interferon and ribavirin nonresponders.
Rustgi VK; Lee WM; Lawitz E; Gordon SC; Afdhal N; Poordad F; Bonkovsky HL; Bengtsson L; Chandorkar G; Harding M; McNair L; Aalyson M; Alam J; Kauffman R; Gharakhanian S; McHutchison JG;
Hepatology; 2009 Dec; 50(6):1719-26. PubMed ID: 19852040
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial comparing pegylated interferon alpha-2b versus pegylated interferon alpha-2a, both plus ribavirin, to treat chronic hepatitis C in human immunodeficiency virus patients.
Laguno M; Cifuentes C; Murillas J; Veloso S; Larrousse M; Payeras A; Bonet L; Vidal F; Milinkovic A; Bassa A; Villalonga C; Pérez I; Tural C; Martínez-Rebollar M; Calvo M; Blanco JL; Martínez E; Sánchez-Tapias JM; Gatell JM; Mallolas J
Hepatology; 2009 Jan; 49(1):22-31. PubMed ID: 19085908
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
[TBL] [Abstract][Full Text] [Related]
15. CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients: A prospective, randomized study.
Zhang K; Cao H; Liang J; Shu X; Sun H; Li G; Xu Q
Medicine (Baltimore); 2016 Aug; 95(31):e4471. PubMed ID: 27495085
[TBL] [Abstract][Full Text] [Related]
16. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.
Foster GR
Expert Opin Pharmacother; 2003 May; 4(5):685-91. PubMed ID: 12739994
[TBL] [Abstract][Full Text] [Related]
18. [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
Wang M; Zheng W; Zhang H; Li Z; Jiang D; Liu Y; Zhou R; Li XG; Zhang Y; Zhang Z; Wu S; Zhang Y; Li J
Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):255-9. PubMed ID: 25173222
[TBL] [Abstract][Full Text] [Related]
19. Studies of therapy with thymosin alpha1 in combination with pegylated interferon alpha2a and ribavirin in nonresponder patients with chronic hepatitis C.
Camerini R; Ciancio A; DE Rosa A; Rizzetto M
Ann N Y Acad Sci; 2007 Sep; 1112():368-74. PubMed ID: 17600286
[TBL] [Abstract][Full Text] [Related]
20. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation.
Shepherd J; Jones J; Hartwell D; Davidson P; Price A; Waugh N
Health Technol Assess; 2007 Mar; 11(11):1-205, iii. PubMed ID: 17346498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
